Misonix, Inc. (MSON) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Misonix, Inc. (MSON) trades at $26.54 with AI Score 49/100 (Grade C). Misonix, Inc. designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for MSON: MSON does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MSON against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MSON: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Misonix, Inc. (MSON) Healthcare & Pipeline Overview
Misonix, Inc. specializes in minimally invasive surgical ultrasonic medical devices, including BoneScalpel, SonaStar, and SonicOne. These products cater to diverse clinical specialties like neurosurgery, orthopedics, and wound care, positioning Misonix in a competitive medical device market with a focus on precision and tissue-sparing technology.
What Is the Investment Thesis for MSON?
Misonix, Inc. presents an interesting investment case within the medical device sector. The company's focus on minimally invasive ultrasonic surgical devices caters to a growing demand for precise and tissue-sparing surgical techniques. Key value drivers include the continued adoption of BoneScalpel, SonaStar, and SonicOne systems across various surgical specialties. Growth catalysts include expansion into new international markets and the development of innovative applications for existing product lines. However, the company's negative profit margin of -19.6% raises concerns about profitability and operational efficiency. Investors should closely monitor the company's ability to improve its financial performance and capitalize on its growth opportunities. The beta of 1.35 indicates higher volatility compared to the market.
Based on FMP financials and quantitative analysis
MSON Key Highlights
Misonix operates with a gross margin of 71.1%, indicating strong pricing power and efficient cost management in its manufacturing processes.
- The company's product portfolio includes BoneScalpel, SonaStar, and SonicOne, addressing diverse surgical needs from bone cutting to tumor emulsification and wound debridement.
- Misonix distributes its products through sales representatives and distributors, enabling market penetration in the United States and internationally.
- The company's products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound care, and maxillo-facial surgical applications.
- Misonix has a beta of 1.35, indicating that the stock is more volatile than the overall market.
Who Are MSON's Competitors?
MSON is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALGN Align Technology, Inc. | $158.94 | -2.51% | $11.4B | 85 |
| NVCR Novocure | $17.77 | -2.36% | $2.07B | 55 |
| ABT Abbott Laboratories | $114.26 | -0.15% | $198B | 70 |
| SYK Stryker Corporation | $340.11 | +0.04% | $131B | 79 |
| MDT Medtronic plc | $92.88 | -1.33% | $119B | 77 |
| BSX Boston Scientific Corporation | $52.01 | +3.05% | $77.3B | 80 |
| EW Edwards Lifesciences Corporation | $92.28 | +1.43% | $53.1B | 93 |
| DXCM DexCom, Inc. | $89.92 | +0.04% | $33.9B | 93 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MSON's Key Strengths?
Specialized product portfolio in ultrasonic surgical devices.
- Established presence in neurosurgery, orthopedics, and wound care.
- Proprietary technology and intellectual property.
- Strong gross margin of 71.1%.
What Are MSON's Weaknesses?
Negative profit margin of -19.6%.
- Limited scale compared to larger medical device companies.
- Reliance on a relatively small number of key products.
- High beta indicating increased volatility.
What Could Drive MSON Stock Higher?
Continued adoption of BoneScalpel, SonaStar, and SonicOne systems in various surgical specialties.
- Potential regulatory approvals for new product applications.
- Expansion into new international markets.
- Strategic partnerships or acquisitions to expand product portfolio.
What Are the Key Risks for MSON?
Negative return on equity (-10.3%) — the business is not currently generating profit on shareholder capital.
- Intense competition from established medical device companies.
- Technological advancements by competitors.
- Regulatory changes and healthcare reforms.
- Negative profit margin impacting financial performance.
What Are the Growth Opportunities for MSON?
- Expansion into Emerging Markets: Misonix has the opportunity to expand its presence in emerging markets, where demand for advanced surgical technologies is growing rapidly. These markets often have less competition and offer the potential for significant revenue growth. Focusing on regions with developing healthcare infrastructure and increasing healthcare spending could drive adoption of Misonix's products. This expansion could contribute significantly to revenue growth within the next 3-5 years.
- Development of New Applications: Misonix can leverage its existing ultrasonic technology to develop new applications for its products in different surgical specialties. This could involve adapting the BoneScalpel, SonaStar, or SonicOne systems for use in areas such as cardiovascular surgery, cosmetic surgery, or dental surgery. Investing in research and development to explore these new applications could lead to significant market expansion and increased revenue streams over the next 2-4 years.
- Strategic Partnerships and Acquisitions: Misonix can pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. Partnering with companies that have complementary technologies or distribution networks could accelerate growth and enhance Misonix's competitive position. Acquiring smaller companies with innovative surgical devices could also add new revenue streams and expand the company's addressable market within the next 1-3 years.
- Increased Focus on Wound Care Market: The wound care market represents a significant growth opportunity for Misonix, particularly with its SonicOne ultrasonic debridement system. As the prevalence of chronic wounds continues to rise due to factors such as diabetes and aging populations, the demand for advanced wound care technologies is increasing. Misonix can capitalize on this trend by expanding its sales and marketing efforts in the wound care market and developing new applications for SonicOne in this area. This could yield substantial growth within the next 2 years.
- Enhancement of Training and Education Programs: Misonix can invest in enhancing its training and education programs for surgeons and healthcare professionals who use its products. Providing comprehensive training on the proper use and benefits of BoneScalpel, SonaStar, and SonicOne can drive adoption and increase customer satisfaction. This can also help to establish Misonix as a leader in the field of ultrasonic surgical devices and foster long-term relationships with key customers. This ongoing effort will contribute to sustained growth.
What Are MSON's Competitive Advantages?
- Proprietary ultrasonic technology in surgical devices.
- Established brand reputation in specific surgical applications.
- Specialized product portfolio catering to niche markets.
- Strong relationships with surgeons and healthcare professionals.
What Does MSON Do?
Founded in 1959 and based in Farmingdale, New York, Misonix, Inc. has evolved into a prominent player in the design, development, manufacture, and marketing of minimally invasive surgical ultrasonic medical devices. The company's core product lines include the BoneScalpel, SonaStar, and SonicOne systems. The BoneScalpel is an ultrasonic bone cutting and sculpting system used in surgical procedures requiring precise bone manipulation while minimizing soft tissue damage. SonaStar is a surgical aspirator designed to emulsify and remove both soft and hard tumors, primarily utilized in neurosurgery and general surgery. SonicOne is an ultrasonic cleansing and debridement system that facilitates tissue-specific debridement and cleansing of wounds and burns, effectively removing devitalized tissue and fibrin deposits while preserving viable cells. Misonix's products find application across various clinical specialties, including neurosurgery, orthopedic surgery, general surgery, plastic surgery, wound care, and maxillo-facial surgical applications. The company distributes its products through a combination of direct sales representatives and distributors, extending its reach both within the United States and internationally. Misonix continues to innovate in the ultrasonic surgical device space, focusing on solutions that enhance surgical precision and patient outcomes.
What Products and Services Does MSON Offer?
- Designs minimally invasive surgical ultrasonic medical devices.
- Develops ultrasonic bone cutting and sculpting systems (BoneScalpel).
- Manufactures surgical aspirators for tumor emulsification and removal (SonaStar).
- Markets ultrasonic cleansing and debridement systems for wound care (SonicOne).
- Sells products through sales representatives and distributors.
- Provides solutions for neurosurgery, orthopedic surgery, and general surgery.
How Does MSON Make Money?
- Designs, manufactures, and sells ultrasonic surgical devices.
- Generates revenue through direct sales and distribution partnerships.
- Focuses on minimally invasive surgical solutions for various clinical specialties.
What Industry Does MSON Operate In?
Misonix operates within the medical device industry, a sector characterized by continuous innovation and increasing demand for minimally invasive surgical solutions. The market for ultrasonic surgical devices is driven by the need for precision, reduced patient trauma, and faster recovery times. Competition in this space is intense, with established players and emerging companies vying for market share. Misonix's focus on specific applications like bone cutting, tumor emulsification, and wound debridement allows it to carve out a niche within this competitive landscape.
Who Are MSON's Key Customers?
- Hospitals and surgical centers.
- Neurosurgeons and orthopedic surgeons.
- Wound care specialists.
- General surgeons.
Earnings Track Record
Misonix, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 22.6% above estimates on average.
MSON Valuation & Market Position
Relative to its peer group, MSON's quantitative score of 49/100 is below the peer average of 73/100.
Key Financial Metrics
Return on equity for Misonix, Inc. stands at -10.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.3%, showing how much profit it generates from its asset base. A current ratio of 2.61 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.7%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Misonix, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Farmingdale, US. The company is led by CEO Stavros George Vizirgianakis. MSON has traded publicly since 1992.
MSON Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Misonix's future, indicating insiders believe the stock is undervalued.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative medical devices and growth potential.
- Misonix's recent product launches have generated excitement among healthcare professionals, enhancing its market position.
- The overall trend in the medical device sector remains strong, with increasing demand for advanced surgical tools bolstering Misonix's prospects.
Bear Case
- Concerns over regulatory hurdles have surfaced, potentially delaying product approvals and impacting growth timelines.
- Some community members express skepticism about Misonix's ability to compete with larger players in the medical device space.
- Recent earnings reports have shown mixed results, leading to uncertainty about the company's short-term financial health.
- Market sentiment remains cautious, with discussions reflecting worries about broader economic conditions affecting healthcare spending.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MSON Latest News
No recent news available for MSON.
MSON Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MSON.
Price Targets
Wall Street price target analysis for MSON.
MSON MoonshotScore
What does this score mean?
The MoonshotScore rates MSON 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Stavros George Vizirgianakis
CEO
Stavros George Vizirgianakis serves as the CEO of Misonix, Inc. His background includes extensive experience in the medical device industry, with a focus on strategic leadership and operational excellence. Prior to joining Misonix, he held various leadership positions at medical technology companies, where he was responsible for driving growth and innovation. His expertise spans areas such as product development, sales and marketing, and business development. He is responsible for managing 281 employees.
Track Record: Under Stavros George Vizirgianakis's leadership, Misonix has focused on expanding its product portfolio and market reach. He has overseen the development and launch of new applications for the company's existing product lines, as well as the implementation of strategic initiatives to improve operational efficiency. Key milestones under his tenure include expanding into new international markets and strengthening relationships with key customers.
Misonix, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for MSON?
MSON holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Misonix, Inc. designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices. Their product portfolio includes systems for bone cutting, tumor emulsification …
What does Misonix, Inc. do?
Misonix, Inc. designs, develops, manufactures, and markets minimally invasive surgical ultrasonic medical devices. The company's product lines include the BoneScalpel, an ultrasonic bone cutting and sculpting system; SonaStar, a surgical aspirator for tumor emulsification; and SonicOne, an ultrasonic cleansing and debridement system for wound care.
What do analysts say about MSON stock?
Analyst coverage of MSON stock is limited, but generally focuses on the company's growth potential within the medical device sector. Key valuation metrics include revenue growth, gross margin, and profitability. Analysts often consider the company's ability to expand its market share and develop new applications for its existing product lines.
What are the main risks for MSON?
The main risks for Misonix include intense competition from established medical device companies, technological advancements by competitors, regulatory changes and healthcare reforms, and the company's negative profit margin. The competitive landscape could impact Misonix's ability to maintain market share and pricing power. Technological advancements by competitors could render Misonix's products obsolete.
What are the key factors to evaluate for MSON?
Misonix, Inc. (MSON) holds an AI score of 49/100 (low). presents an interesting investment case within the medical device sector. Not financial advice.
How frequently does MSON data refresh on this page?
MSON's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MSON's recent stock price performance?
Misonix, Inc. (MSON) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product portfolio in ultrasonic surgical devices. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MSON overvalued or undervalued right now?
Misonix, Inc. (MSON) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MSON before investing?
Before investing in Misonix, Inc. (MSON), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on provided source data and may not reflect the most current developments.